ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

FDA Concludes Safety Review Of Novartis MS Drug Gilenya

By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The U.S. Food and Drug Administration Monday said Novartis AG's (NVS, NOVN.VX) multiple-sclerosis drug Gilenya shouldn't be used in patients with a recent history of stroke or some types of heart problems, concluding a safety review of the drug. The safety review was prompted by a report last November of a 59-year-old patient dying in the U.S. less than 24 hours after taking the first dose of the drug. The agency said it continues to recommend that doctors closely monitor the hearts of patients after they have been given the first dose of the drug because the product can lower a person's heart rate temporarily. As for the patient's death, the FDA said an exact cause of death couldn't be identified. The FDA said the patient had extensive brainstem MS lesions, which also have been associated with sudden death. The FDA also said it looked at other deaths that appeared to be from cardiovascular causes in patients who had been taking Gilenya and concluded that the drug's "contribution to the death was unclear." The FDA said the drug shouldn't be used in patients who have had a stroke or heart trouble within the past six months. The agency also said the drug shouldn't be used in patients taking some kinds of antiarrhythmic heart medicines. -By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
07/29/201508:10:07GSK Posts Sharp Fall in Profit
07/29/201507:29:46Novartis Spins Off Three Pipeline Drugs Into New Company
07/22/201519:45:14ADRs End Lower; National Bank of Greece, Petrobras Trade Actively
07/21/201518:40:12ADRs End Mixed; Infosys Rises
07/21/201515:19:03Novartis Can Sell Copycat of Amgen's Neupogen in September, Court...
07/21/201502:42:34Novartis Pressured by Dollar Strength -- Update
07/21/201502:40:10Novartis Pressured by Dollar Strength
07/21/201502:27:09Novartis Pressured by Dollar Strength
07/21/201501:53:33Novartis Pressured by Dollar Strength
07/17/201509:00:55Novartis AG 2Q 2015 -- Forecast
07/14/201507:13:03Midyear Report Card: Grading My Biotech Predictions for 2015
07/12/201511:02:03$1.5 Trillion Reasons to Invest in These Companies
07/09/201516:04:03This Week's Top Healthcare News Could Cause These Stocks Pop...
07/07/201519:52:49Novartis's Heart Failure Drug Is Approved by FDA - Update
07/07/201519:29:13Novartis's Heart Failure Drug Is Approved by FDA - Update
07/07/201518:00:18Novartis Heart Failure Drug Approved by FDA
07/07/201517:57:19Novartis Heart Failure Drug Approved by FDA
07/02/201503:48:47Ergomed Appoints Andrew Mackie as Chief Business Officer
06/29/201517:51:48ADRs End Lower; National Bank of Greece Drops Sharply
06/29/201503:39:07Novartis Buys Drug Development Company Spinifex Pharmaceuticals

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad